Oxytocin Market Size, Share & Trends Report

Oxytocin Market (2024 - 2030) Size, Share & Trends Analysis Report By Indication (Antepartum, Postpartum), By Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies), By Region, And Segment Forecasts

Market Segmentation

Women’s Health Application Outlook (Revenue in USD Million, 2018 - 2030)
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
Women’s Health Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Hormonal Therapies
- Bone Health Agents
- Fertility Agents
- GnRH Modulators
- Pain and Symptom Management
- Metabolic Agents
- Others
Women’s Health Age Outlook (Revenue in USD Million, 2018 - 2030)
- 50 years and above
  - Postmenopausal osteoporosis
  - Endometriosis & uterine fibroids
  - Menopause
  - Others
- Others
Women’s Health Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal infertility
    - Contraceptives
    - Postmenopausal osteoporosis
    - Endometriosis & uterine fibroids
    - Menopause
    - Polycystic ovary syndrome (PCOS)
  - North America Drug Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal Therapies
    - Bone Health Agents
    - Fertility Agents
    - GnRH Modulators
    - Pain and Symptom Management
    - Metabolic Agents
    - Others
  - North America Age Outlook (Revenue in USD Million, 2018 - 2030)
    - 50 years and above
      - Postmenopausal Osteoporosis
      - Endometriosis & Uterine Fibroids
      - Menopause
      - Others
    - Others
  - U.S.
    - U.S. Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - U.S. Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - U.S. Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal Osteoporosis
        
        Endometriosis & Uterine Fibroids
        
        Menopause
        
        Others
      - Others
  - Canada
    - Canada Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Canada Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Canada Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal Osteoporosis
        
        Endometriosis & Uterine Fibroids
        
        Menopause
        
        Others
      - Others
  - Mexico
    - Mexico Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Mexico Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Mexico Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
- Europe
  - Europe Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal infertility
    - Contraceptives
    - Postmenopausal osteoporosis
    - Endometriosis & uterine fibroids
    - Menopause
    - Polycystic ovary syndrome (PCOS)
  - Europe Drug Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal Therapies
    - Bone Health Agents
    - Fertility Agents
    - GnRH Modulators
    - Pain and Symptom Management
    - Metabolic Agents
    - Others
  - Europe Age Outlook (Revenue in USD Million, 2018 - 2030)
    - 50 years and above
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Others
    - Others
  - Germany
    - Germany Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Germany Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Germany Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - UK
    - UK Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - UK Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - UK Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - France
    - France Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - France Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - France Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Italy
    - Italy Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Italy Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Italy Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Spain
    - Spain Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Spain Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Spain Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Denmark
    - Denmark Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Denmark Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Denmark Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Sweden
    - Sweden Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Sweden Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Sweden Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Norway
    - Norway Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Norway Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Norway Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
- Asia Pacific
  - Asia Pacific Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal infertility
    - Contraceptives
    - Postmenopausal osteoporosis
    - Endometriosis & uterine fibroids
    - Menopause
    - Polycystic ovary syndrome (PCOS)
  - Asia Pacific Drug Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal Therapies
    - Bone Health Agents
    - Fertility Agents
    - GnRH Modulators
    - Pain and Symptom Management
    - Metabolic Agents
    - Others
  - Asia Pacific Age Outlook (Revenue in USD Million, 2018 - 2030)
    - 50 years and above
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Others
      - Others
  - China
    - China Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - China Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - China Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Japan
    - Japan Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Japan Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Japan Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - India
    - India Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - India Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - India Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Thailand
    - Thailand Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Thailand Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Thailand Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - South Korea
    - South Korea Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - South Korea Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - South Korea Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Australia
    - Australia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Australia Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Australia Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
- Latin America
  - Latin America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal infertility
    - Contraceptives
    - Postmenopausal osteoporosis
    - Endometriosis & uterine fibroids
    - Menopause
    - Polycystic ovary syndrome (PCOS)
  - Latin America Drug Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal Therapies
    - Bone Health Agents
    - Fertility Agents
    - GnRH Modulators
    - Pain and Symptom Management
    - Metabolic Agents
    - Others
  - Latin America Age Outlook (Revenue in USD Million, 2018 - 2030)
    - 50 years and above
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Others
    - Others
  - Brazil
    - Brazil Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Brazil Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Brazil Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Argentina
    - Argentina Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Argentina Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Argentina Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
- Middle East and Africa
  - Middle East and Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal infertility
    - Contraceptives
    - Postmenopausal osteoporosis
    - Endometriosis & uterine fibroids
    - Menopause
    - Polycystic ovary syndrome (PCOS)
  - Middle East and Africa Drug Outlook (Revenue in USD Million, 2018 - 2030)
    - Hormonal Therapies
    - Bone Health Agents
    - Fertility Agents
    - GnRH Modulators
    - Pain and Symptom Management
    - Metabolic Agents
    - Others
  - Middle East and Africa Age Outlook (Revenue in USD Million, 2018 - 2030)
    - 50 years and above
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Others
    - Others
  - South Africa
    - South Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - South Africa Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - South Africa Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Saudi Arabia
    - Saudi Arabia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Saudi Arabia Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Saudi Arabia Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - UAE
    - UAE Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - UAE Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - UAE Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others
  - Kuwait
    - Kuwait Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal infertility
      - Contraceptives
      - Postmenopausal osteoporosis
      - Endometriosis & uterine fibroids
      - Menopause
      - Polycystic ovary syndrome (PCOS)
    - Kuwait Drug Outlook (Revenue in USD Million, 2018 - 2030)
      - Hormonal Therapies
      - Bone Health Agents
      - Fertility Agents
      - GnRH Modulators
      - Pain and Symptom Management
      - Metabolic Agents
      - Others
    - Kuwait Age Outlook (Revenue in USD Million, 2018 - 2030)
      - 50 years and above
        
        Postmenopausal osteoporosis
        
        Endometriosis & uterine fibroids
        
        Menopause
        
        Others
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments